Hematopoietic cancers accounted for 23.9% of cases in patients with LIG4 deficiency, particularly lymphomas (both EBV-positive and EBV-negative), lymphoid leukemias, and MDS. Here, LIG4 is linked to hematopoietic and lymphoid cell neoplasm.